Better Mental Health for More People
We are at a crisis point in the field of mental health provision and Addiction treatment
Mental health and addictions are the 5th leading cause of illness globally, affecting 20% of the global population. The global substance Addiction treatment industry is valued at USD17.5bn per annum and is forecast to increase to USD31.5bn per annum by 2027.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change Addiction treatment and deliver significantly better patient outcomes.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through our development and delivery divisions.
We have a dual strategic focus, to research, develop and commercialise psychedelic new chemical entity drugs, therapies, and enabling technologies to treat Addiction. And to build, own and operate the UK and EU’s leading chain of medical psychedelic clinics that treat Addiction amongst other mental health conditions.
Our goal is to be the leader in both the development of these drugs and the delivery of them through our clinics and scale our reach through our licensing partnerships.
Clear IP development pathway
• New chemical entity drugs
• Clinical trials
• Advanced predictive analytics
Multiple revenue streams:
• Clinic revenue starting in 2021.
• Partnership Ecosystem revenue starting in 2022.
• Research revenue in 2026+.
First mover advantage in UK and EU:
400m people and CAD$25trn GDP.
Global research leaders in the field of psychedelic treatments for Addiction:
Dr. Ben Sessa led the world’s only MDMA-Assisted Psychotherapy and AUD study (BIMA) and Prof. Celia Morgan led the world’s only Ketamine-Assisted Psychotherapy AUD study (KARE).
The leading scientific and medical team in the industry:
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan,, Dr. Michael Mithoefer, Ann Mithoefer, and Prof. Matt Johnson.
Strategic partnerships with two leading UK universities
for exclusive access to data and findings from recent clinics trials.
Mental health and Addictions are the 5th leading cause of illness globally, affecting 20% of the global population.
It costs the EU, US, and UK economies US$1.5trn
in lost economic activity per annum.
The global substance Addiction treatment industry is valued at USD17.5bn per annum and is forecast to increase to USD31.5bn per annum by 2027.
US and EU
US accounts for 40% of this market, Europe 30%, Rest of World 20%.
Alcohol Use Disorder accounts for 30% of the treatment market.